Opportunistic Salpingectomy at Benign Hysterectomy: Evaluating the Evidence

Opportunistic Salpingectomy at Benign Hysterectomy: Evaluating the Evidence

Opportunistic salpingectomy refers to the removal of both fallopian tubes during another gynecologic surgery (such as a hysterectomy for benign disease) in women at average risk of ovarian cancer. This strategy is motivated by evidence that many high-grade serous ovarian cancers actually originate as serous tubal intraepithelial carcinomas in the fallopian tubes.

By removing the tubes "opportunistically" during a routine benign hysterectomy (while preserving the ovaries), the hope is to reduce future ovarian cancer risk without inducing surgical menopause. Below, we examine recent evidence (primarily from the last five years) supporting opportunistic salpingectomy in low-risk women, evidence or perspectives questioning or opposing routine opportunistic salpingectomy, and studies comparing hysterectomy with vs. without salpingectomy in terms of outcomes.

Evidence Supporting Opportunistic Salpingectomy in Low-Risk Women

Reduction in Ovarian Cancer Risk: A growing body of research indicates that performing a bilateral salpingectomy in average-risk women can significantly reduce the incidence of epithelial ovarian cancer. A twenty twenty-five systematic review and meta-analysis (including over five point seven million patients from multiple countries) found that women who underwent prophylactic salpingectomy had a significantly lower risk of developing ovarian cancer compared to those who did not. In particular, bilateral salpingectomy was associated with an approximate fifty-two percent relative risk reduction in ovarian cancer (pooled odds ratio approximately zero point forty-eight, ninety-five percent confidence interval zero point thirty-three to zero point sixty-nine). Unilateral salpingectomy did not significantly reduce risk (as expected, since one tube remains). These findings align with earlier population studies: for example, a Danish registry study found bilateral salpingectomy was associated with approximately forty-two percent lower odds of ovarian cancer (adjusted odds ratio approximately zero point fifty-eight) compared to no salpingectomy. Similarly, a Swedish cohort reported a substantially reduced ovarian cancer incidence in women who had prior salpingectomies. More recently, a Canadian cohort analysis observed fewer ovarian cancers than expected among women who had undergone opportunistic salpingectomy, particularly a significant decrease in high-grade serous cancers. Taken together, these data strongly suggest that removing the fallopian tubes during benign gyn surgeries can meaningfully lower the future risk of tubo-ovarian cancer in average-risk women.

Surgical Safety and Ovarian Function: Crucially, adding a salpingectomy does not appear to impose significant surgical or physiologic harm. Multiple studies have examined whether removing the tubes (which share blood supply with the ovaries and uterus) might increase operative complications or compromise ovarian function. The evidence to date is reassuring:

· Operative Outcomes: Several large observational studies and reviews have reported no significant increase in surgical complication rates when a salpingectomy is added to a benign hysterectomy. In a regional initiative in British Columbia (OVCARE study), for example, the addition of bilateral salpingectomy did not increase the risk of hospital readmission or need for blood transfusion compared to hysterectomy alone. The only notable difference was a modest increase in operative time - on the order of about ten to twenty extra minutes for removal of the tubes. This is consistent with other reports that find no change in blood loss, length of hospital stay, or conversion to open surgery, and only a slight prolongation of surgery when performing opportunistic salpingectomy. Notably, a twenty seventeen systematic review focusing on low-risk premenopausal women found that incorporating prophylactic salpingectomy into routine hysterectomy did not adversely affect operative or postoperative outcomes. Overall, the current evidence indicates that hysterectomy with opportunistic salpingectomy is just as safe as hysterectomy alone in terms of perioperative risks.

· Ovarian Reserve and Menopause: Because the ovaries are retained, an important question is whether opportunistic salpingectomy might nonetheless impair ovarian blood supply or hasten menopause. Data from both biochemical and clinical outcomes are encouraging. A comprehensive review by Kotlyar et al. and other hormonal studies have shown no significant decline in ovarian reserve attributable to salpingectomy. For instance, a prospective study measuring anti-Müllerian hormone, follicle-stimulating hormone, antral follicle counts, etc., found that women who had bilateral salpingectomy during laparoscopic hysterectomy had no difference in ovarian "age" up to five years post-surgery compared to those who did not. Furthermore, a randomized controlled trial in twenty eighteen compared laparoscopic hysterectomy with vs. without prophylactic salpingectomy in premenopausal women and found no adverse impact on ovarian reserve (based on postoperative anti-Müllerian hormone levels) and no increase in surgical complications or recovery time with the added salpingectomy. A twenty nineteen Cochrane review pooled five randomized controlled trials' hormonal data and likewise found no evidence of a significant difference in postoperative ovarian function between hysterectomy-with-opportunistic-salpingectomy versus hysterectomy-alone; the mean change in anti-Müllerian hormone was small and not clinically meaningful (ninety-five percent confidence interval ranged from a slight increase to a slight decrease). At most, the data could allow for an earlier menopausal timing of only approximately twenty months in the opportunistic salpingectomy group, which was deemed not clinically significant. In fact, in that Cochrane analysis the results "were compatible with no difference" in ovarian reserve, and the authors concluded there was no clinically relevant reduction in anti-Müllerian hormone attributable to adding salpingectomy. Recent prospective studies also support the lack of any meaningful effect on menopausal symptoms: in a twenty twenty-five pilot study, women who underwent hysterectomy with salpingectomy reported no worsening of menopausal symptom scores at six months post-op, compared to slight symptom increases in those who had hysterectomy alone. (Notably, in that study the vast majority of eligible women chose to have opportunistic salpingectomy when counseled, reflecting patient preference for cancer risk-reduction.) In summary, removing the fallopian tubes does not appear to compromise ovarian hormonal function or trigger premature menopause in low-risk women, especially when compared to the much larger impact that removing ovaries would have.

· Quality of Life and Other Outcomes: Studies have also looked at broader outcomes. Early data indicate that performing opportunistic salpingectomy has no detrimental effect on quality of life or sexual function after surgery. In other words, patients' postoperative well-being, including sexual health, is equivalent whether or not the tubes were removed during their hysterectomy. Additionally, opportunistic salpingectomy may confer some ancillary benefits. For example, one retrospective study found that women who had their tubes removed at hysterectomy had a lower need for re-operation for benign tubo-ovarian issues later (such as hydrosalpinx or abscess), suggesting opportunistic salpingectomy might prevent future tubal pathology requiring surgery. There is also evidence that salpingectomy (instead of tubal ligation) is a highly effective means of sterilization with the added cancer prevention benefit this has led to salpingectomy being favored over clip or ligature methods for women requesting sterilization at time of cesarean or other surgery.

Endorsement by Medical Organizations: Given the above benefits and minimal downsides, many professional bodies now support opportunistic salpingectomy in appropriate patients. The International Federation of Gynecology and Obstetrics released a position statement endorsing OS as a preventative strategy for ovarian cancer in women undergoing pelvic surgery who have completed childbearing. Likewise, the Society of Gynecologic Oncology and the American College of Obstetricians and Gynecologists have recommended offering bilateral salpingectomy for ovarian cancer risk reduction, even in women at average risk, at the time of benign hysterectomy or in lieu of tubal ligation. In fact, OS is now considered a "best practice" in the United States for ovarian cancer prevention in low-risk women undergoing gynecologic surgery. This shift in practice is reflected in real-world trends: the rate of opportunistic salpingectomy during benign hysterectomies has risen sharply in the last decade. For example, U.S. data showed adoption of OS increased from under ten percent of benign hysterectomies in the early twenty tens to nearly thirty-five to forty percent by twenty twenty. Some regions have adoption rates even higher; in British Columbia, over fifty percent of benign hysterectomies now include removal of tubes as part of a province-wide ovarian cancer prevention initiative. Globally, at least half a dozen countries (e.g. Canada, United States, Denmark, The Netherlands, etc.) have issued guidelines encouraging OS in principle, and many others are actively evaluating the approach.

Cost-Effectiveness: From a public health perspective, opportunistic salpingectomy appears to be highly cost-effective as a cancer prevention measure. Modeling studies have estimated that performing OS during routine surgeries could significantly reduce ovarian cancer cases and save healthcare costs. For instance, a twenty fifteen Markov model showed that adding salpingectomy at hysterectomy was actually less costly than hysterectomy alone (due to future cancer cases averted). Subsequent analyses projected that wide implementation of OS could reduce ovarian cancer incidence by roughly twenty to forty percent over time. One U.S. model calculated that if salpingectomy truly reduces ovarian cancer risk by approximately sixty-five percent, about five thousand three hundred ovarian cancer cases per year (approximately thirty-nine percent of cases) could eventually be prevented in the U.S., translating to hundreds of millions of dollars saved annually in treatment costs. Another study estimated that universal salpingectomy in eligible women might save around four hundred forty-five million dollars in healthcare costs per year in the U.S.. Thus, OS not only has clinical benefit but also makes economic sense as a preventive strategy.

In summary, the case for opportunistic salpingectomy is supported by substantial evidence: it likely cuts ovarian cancer risk roughly in half for average-risk women, without adding surgical morbidity or compromising ovarian function, and it is endorsed by major gynecologic societies. Given the lethality of ovarian cancer and the lack of effective screening, this proactive approach during benign surgeries is an appealing opportunity. As one review concluded, adding salpingectomy at hysterectomy "should be discussed with each woman ... with a clear overview of benefits and risks," since the available data indicate meaningful benefit with minimal harm.